Abbott Labs performing well despite huge drop-off in Covid test sales

Despite a massive drop-off in sales of Covid-19 tests, Abbott Laboratories still performed better than analysts' expectations in the first quarter. The drug giant (NYSE: ABT), with headquarters between Chicago and Milwaukee, reported first-quarter results that bested analysts' expectations on Wednesday, including sales of $9.7 billion, down more than 18% from a year earlier, and adjusted earnings per share of $1.03, down 40% from $1.73 during the same time frame last year. Analysts polled by Thomson …
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news